Of course it doesn't take a great deal of
money to own a significant fraction of CNSI....
Was surfing their website and came across this.
I'm sure somebody posted it ages ago, but will
dredge it up again:
Aptiganel/CERESTAT
Phase III trials in stroke and traumatic brain injury
halted in 1997. Company is pursuing further development
opportunities. Based on input from an independent panel
of stroke experts and our review of the data from the
aptiganel trials, we remain focused on pursuing funding
for another stroke trial. Is that still true?
cambneuro.com
Maybe Aptiganel would be part of a cocktail, and the
"increase in systolic blood pressure" and "excess CNS
effects" would have to be addressed. (?) Just seems
like any neuroprotective agent, even having failed PIII
has to have some value on the chance they can still
redesign the drug or its admisnistration and make it work.
Disclaimer...when CNSI sagged from the high above $3 to
$2 I loaded up...so sure, I am grasping a bit here. But
a marketcap of 25M means that if they ever pull out any
sort of a surprise rabbit out of their hat...nice. IMHO,
agreements with Bayer and Allergan pay the salaries and
rent...so cash should be of no concern whatsoever in
the years ahead.
Final note...the chart shows 5161 as phase I, but that
will be phase II soon later this year.
Message 12697555
Regarding the biotech crash: I had temporarily diversified
back in early March, and happened to have a snapshot of
that portfolio. I ran through the quotes to see what
it cost me to go back and try and trade in that environment
of falling knives through March and April: 300k, or about
a third of this biotech experiment. Not to happy about that,
and it doesn't really ease the pain to call it house money.
Funny how knives become bad trades and become invesments.
In for the long haul now for sure!
Finally, my trial to Neuroinvestment expired, so I'll be
even more blind than usual. Will have to work on the wife.
Feeling poor after biotech got whacked, hehheh. |
